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Osteoclasts are bone-resorbing cells essential for skeletal development, homeostasis, and regeneration. They
derive from hematopoietic progenitors in the monocyte/macrophage lineage and differentiate in response to
RANKL. However, the precise nature of osteoclast progenitors is a longstanding and important question. Using
inducible peroxisome proliferator-activated receptor  (PPAR)-tTA TRE-GFP (green fluorescent protein)
reporter mice, we show that osteoclast progenitors reside specifically in the PPAR-expressing hematopoietic
bone marrow population and identify the quiescent PPAR cells as osteoclast progenitors. Importantly, two
PPAR-tTA TRE-Cre-controlled genetic models provide compelling functional evidence. First, Notch activa-
tion in PPAR cells causes high bone mass due to impaired osteoclast precursor proliferation. Second,
selective ablation of PPAR cells by diphtheria toxin also causes high bone mass due to decreased osteoclast
numbers. Furthermore, PPAR cells respond to both pathological and pharmacological resorption-enhanc-
ing stimuli. Mechanistically, PPAR promotes osteoclast progenitors by activating GATA2 transcription.
These findings not only identify the long-sought-after osteoclast progenitors but also establish unprecedented
tools for their visualization, isolation, characterization, and genetic manipulation.
Bone is a dynamic tissue that constantly remodels itself by
balancing osteoclast-mediated bone resorption and osteoblast-
mediated bone formation. Osteoclasts derive from hematopoi-
etic progenitors (5) in the monocyte/macrophage lineage (41,
47); in contrast, osteoblasts are of mesenchymal lineage (38).
Physiological osteoclast functions are essential for skeletal de-
velopment, homeostasis, and regeneration in response to in-
jury. However, pathological increases in osteoclast activities
are associated with several diseases, including osteoporosis,
arthritis, and bone metastasis of cancers (35).
Osteoclast lineage specification is a multistep process that
requires osteoclast progenitor commitment (41, 47), macro-
phage colony-stimulating factor (M-CSF)-mediated osteoclast
precursor proliferation (57), and RANKL (receptor activator
of NF-B ligand)-mediated osteoclast differentiation (8, 29,
56). Although the discovery of RANKL has revolutionized
research in osteoclast biology, RANKL mainly acts at later
stages of osteoclastogenesis. The cellular identity and the pre-
cise nature of the bona fide osteoclast progenitors are under-
explored. Previous studies have elegantly characterized the cell
surface markers that enrich osteoclast progenitors using flow
cytometry (25); however, tools are lacking to label osteoclast
progenitors in vivo for visualization, isolation, and lineage trac-
ing, as well as to genetically manipulate osteoclast progenitors
for functional characterization.
Peroxisome proliferator-activated receptor  (PPAR) is a
member of the nuclear receptor family of transcription factors
that can be activated by lipophilic ligands, including the dia-
betic drug rosiglitazone (BRL, or Avandia) (18, 49). Previous
studies showed that PPAR is highly expressed in both mono-
cyte/macrophage precursors and mature osteoclasts (39, 48,
52). Loss of PPAR function in mouse hematopoietic lineages
causes osteoclast defects manifested as osteopetrosis (52).
Gain of PPAR function by pharmacological activation en-
hances osteoclastogenesis and bone resorption in mice and
humans (52, 53, 59). These findings provide important mech-
anistic understanding of the clinically reported bone loss and
higher fracture rates in diabetic patients treated with rosigli-
tazone. Here, we hypothesize that osteoclast progenitors reside
in the PPAR-expressing hematopoietic bone marrow popu-
lation and that PPAR regulation goes beyond osteoclast dif-
ferentiation by also defining the osteoclast progenitors.
MATERIALS AND METHODS
Mice. PPAR-tTA TRE-H2BGFP mice (46), flox-DTA mice (30), and NICD-
flox mice (55) have been described previously. PPAR-tTA TRE-cre mice were
bred with flox-DTA mice to generate PTDTA mice. PPAR-tTA TRE-cre mice
were bred with NICD-flox mice to generate PTNICD mice. All experiments were
performed using littermate cohorts. All protocols for mouse experiments were
approved by the Institutional Animal Care and Use Committee of the University
of Texas Southwestern Medical Center.
Bone analyses. To evaluate bone volume and architecture by micro-computed
tomography (CT), mouse tibiae were fixed in 70% ethanol and scanned using
a Scanco CT-35 instrument (Scanco Medical) at several resolutions for both
overall tibial assessment (14-m resolution) and structural analysis of trabecular
and cortical bone (7-m resolution). Trabecular bone parameters were calcu-
lated using the Scanco software to analyze the bone scans from the trabecular
region directly distal to the proximal tibial growth plate. Histomorphometric
analyses were conducted using Bioquant Image Analysis software (Bioquant).
TRAP (tartrate-resistant acid phosphatase) staining of osteoclasts was per-
formed using a leukocyte acid phosphatase staining kit (Sigma). ALP staining of
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FIG. 1. The osteoclast lineage resides in the PPAR-expressing bone marrow population. (A) Schematic diagram of the PPAR-tTA
TRE-H2BGFP reporter mouse model. (B) Osteoclast marker expression in ex vivo bone marrow differentiation cultures (n  3). V, vehicle;
R, RANKL; B, BRL (rosiglitazone). The error bars indicate SD. (C and D) Osteoclast colony formation assay. Bone marrow cells were
purified with a 40-m cell strainer, FACS sorted into GFP and GFP populations, and seeded at 100 cells/well. (C) Representative images
of the TRAP-stained differentiation cultures. Scale bars, 25 m. Two wells each for GFP cells (left) and GFP cells (right) are shown; the
second image from the left shows a GFP well with no macrophage colony formation. (D) Average number of mature osteoclasts (Oc) per
well (n  96), showing that the frequency of osteoclast formation was 140-fold higher in the GFP population than in the GFP population
(P  5.7e70). (E to G) The osteoclast lineage resides in the PPAR-expressing bone marrow population in situ. (E) Multinucleated mature
osteoclasts (outlined by dashed lines) differentiated from unsorted bone marrow of PPAR-GFP mice ex vivo were GFP. Scale bars, 25 m.
(F) CD115 monocyte/macrophage precursors (M) in the bone marrow (BM) and CD115 multinucleated osteoclasts at the bone/marrow
boundary were GFP. Scale bars, 4 m. (G) The TRAP (purple) osteoclasts colocalized with the GFP cells in vivo (indicated by yellow
arrowheads). Scale bars, 25 m. (H and I) Microarray analysis of PPAR (GFP) and PPAR (GFP) hematopoietic bone marrow cells
(n  2, from 2 independent reporter mice). (H) Scatterplot of the genes up- or downregulated in the GFP population (1.8-fold; P  0.05)
(red). (I) Heat map illustrating the expression changes of cell-type-specific marker genes.
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osteoblasts was performed using an alkaline phosphatase staining kit (Sigma). As
a bone resorption marker, urinary C-terminal telopeptide fragments of the type
I collagen (CTX-1) was measured with the RatLaps enzyme immunoassay (EIA)
kit (Immunodiagnostic Systems) and normalized by urinary creatinine measured
with the Infinity Creatinine Reagent (Thermo Scientific). As a bone formation
marker, serum osteocalcin was measured with the mouse osteocalcin EIA kit
(Biomedical Technologies Inc.).
Ex vivo osteoclast differentiation. Osteoclasts were differentiated from mouse
bone marrow cells as described previously (52, 53). Briefly, bone marrow cells
were purified with a 40-m cell strainer to remove mesenchymal cells, differen-
tiated with 40 ng/ml of M-CSF (R&D Systems) in  minimal essential medium
(-MEM) containing 10% fetal bovine serum (FBS) for 3 days and then with 40
ng/ml of M-CSF and 100 ng/ml of RANKL (R&D Systems) for 3 days (unless
otherwise stated), with or without BRL (1 M) throughout the time course.
Mature osteoclasts were identified as multinucleated (	3 nuclei) TRAP cells.
Osteoclast differentiation was quantified by the RNA expression of RANKL-
induced transcription factors and osteoclast function genes using reverse tran-
scription-quantitative PCR (RT-QPCR) analysis.
Osteoclast precursor proliferation assay. Osteoclast precursor proliferation
was quantified using a bromodeoxyuridine (BrdU) cell proliferation assay kit
(GE Healthcare Life Sciences) (6). Mouse bone marrow cells were treated with
M-CSF (40 ng/ml) for 3 days to stimulate osteoclast precursor expansion. On day
4, the cells were M-CSF starved for 6 h to synchronize the cell cycle. The cells
were then restimulated with M-CSF for 4 h to induce S phase, during which
BrdU was provided in the culture medium and integrated into the DNA of the
proliferating cells. Osteoclast precursor proliferation was quantified as BrdU
incorporation using the BrdU enzyme-linked immunosorbent assay (ELISA) in
the kit.
Gene expression analyses. RNA was reverse transcribed into cDNA using an
ABI High Capacity cDNA RT Kit and analyzed using real-time quantitative PCR
(SYBR green) in triplicate. All RNA expression was normalized by ribosomal
protein L19.
Promoter analyses. Promoter sequence alignment was performed using Vec-
tor NTI Advanced 11 AlignX software (Invitrogen). Chromatin immunoprecipi-
tation (ChIP) assays were performed using fluorescence-activated cell sorter
(FACS)-sorted green fluorescent protein-positive (GFP) and GFP mouse
bone marrow cells as previously described (52). The antibodies used were
PPAR, PU.1 (Santa Cruz), acetyl-histone H3 (Upstate/Millipore), and IgG
negative control (BD Biosciences). ChIP output was quantified by real-time PCR
in triplicate and normalized by 10% input.
Transfection. Bone marrow cells were purified with a 40-m cell strainer to
remove mesenchymal cells, sorted by FACS into GFP and GFP populations,
and cultured with 40 ng/ml M-CSF overnight. Cells in suspension were removed,
and adherent cells were transfected in the presence of 40 ng/ml M-CSF, using
FuGene HD (Roche) for 3 days before RANKL-induced osteoclast differenti-
ation. The transfection efficiency was 	50%. For GATA2 gain of function, a
plasmid encoding full-length GATA2 (Open Biosystems) or vector control was
transfected. For GATA2 loss of function, small interfering RNA (siRNA) for
GATA2 (siGATA2) or control siRNA (siCtrl) (Santa Cruz) was transfected.
Flow cytometry. The FACS analyses of bone marrow cells were performed
using a BD FACScan flow cytometer and phycoerythrin (PE)-conjugated anti-
bodies (all from BD Pharmingen). The FACS sorting of GFP and GFP bone
marrow cell populations was performed using a MoFlo Cell Sorter (Beckman
Coulter).
Statistical analyses. All statistical analyses were performed with Student’s t
test, and the results are represented as means and standard deviations (SD).
RESULTS
Identification of osteoclast progenitors by in vivo labeling.
To test this hypothesis, we employed our PPAR-GFP re-
porter mice (PPAR-tTA TRE-H2BGFP) (46). In these mice,
a tet transactivator cassette (tTA) was inserted into the endog-
enous PPAR locus. When combined with the tTA-responsive
H2BGFP transgenic allele (TRE-H2BGFP) (26, 51), the big-
enic mice marked PPAR-expressing cells with GFP (Fig. 1A).
We isolated GFP cells from the hematopoietic bone marrow
population by FACS (http://www4.utsouthwestern.edu/wanlab
/publications.htm) and compared their osteoclastogenic poten-
tial with that of GFP cells using an ex vivo osteoclast differ-
entiation assay. Expression of the osteoclast markers c-fos and
TRAP (Fig. 1B), as well as Ctsk, Calcr, and CAR2 (not
shown), indicated that GFP cells differentiated into oste-
oclasts, while such activity appeared to be lacking in GFP
cells.
To quantify osteoclast colony formation, we sorted GFP
and GFP bone marrow cells, plated them at 100 cells/well in
96-well plates, and cultured them with M-CSF until 50% con-
fluence before RANKL stimulation. After 11 days, we stained
the cells for TRAP and quantified mature osteoclasts (TRAP
and 	3 nuclei) in each well. The majority of the GFP cells in
each well had already formed osteoclasts, and the remaining
mononuclear cells were TRAP preosteoclasts in the process
of maturation (Fig. 1C). For GFP wells, both macrophage
and osteoclast colonies developed at 100% (96/96); in contrast,
55% (53/96) of GFP wells developed TRAP macrophage
colonies, and only 7% (4/96) formed osteoclasts. The number
of osteoclasts per well was also significantly higher for GFP
than for GFP wells; as a result, the frequency of osteoclast
formation was 140-fold higher for GFP cells (Fig. 1D), indi-
cating that 	99% of osteoclast progenitors/precursors were
PPAR. These results show that the osteoclast lineage re-
sides in the GFP bone marrow population ex vivo.
Imaging analyses further supported the notion that the os-
teoclast lineage was derived from GFP cells ex vivo and in
vivo. First, we performed ex vivo osteoclast differentiation using
the unsorted bone marrow cells of PPAR-GFP mice. The
multinucleated osteoclasts developed in culture were all GFP
(Fig. 1E). Second, we performed immunostaining of the fem-
oral sections for CD115 (M-CSF receptor [M-CSFR]), a
marker for the monocyte/macrophage lineage. The CD115
multinucleated osteoclasts at the bone/marrow junction were
GFP, and notably, the CD115 monocyte/macrophage pre-
cursors in the bone marrow also expressed GFP (Fig. 1F).
Third, we performed TRAP staining as an independent
method to identify osteoclasts. The TRAP osteoclasts also
colocalized with GFP cells (Fig. 1G). We also observed
GFP bone marrow cells that were TRAP, which represent
putative osteoclast progenitors and precursors (Fig. 1G). Thus,
the osteoclast lineage resides in the GFP bone marrow pop-
ulation in situ.
To compare the gene expression profiles of GFP and
GFP cells, we performed microarray analysis. Approximately
800 genes were up- or downregulated in the GFP population
by 1.8-fold (P  0.05) (Fig. 1H). The GFP cells displayed
increased expression of stem cell/granulocyte-monocyte (GM)
progenitor (26 genes) and macrophage/osteoclast (61 genes)
markers and decreased expression of lymphocyte (20 genes),
mast cell (37 genes), and megakaryocyte/erythrocyte (128
genes) markers (Fig. 1I) (http://www4.utsouthwestern.edu
/wanlab/publications.htm). This suggests that (i) the PPAR
population is enriched for stem/progenitor cells and (ii)
PPAR expression specifically directs hematopoiesis toward
the monocyte/macrophage lineage but away from lymphoid or
other myeloid lineages, including megakaryocytes, erythro-
cytes, and mast cells. Consistently, methylcellulose colony-
forming assays showed that GFP cells generated more
macrophage colonies but fewer granulocyte, erythrocyte,
and lymphocyte colonies than GFP cells (http://www4
.utsouthwestern.edu/wanlab/publications.htm). Together, these data
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indicate that we have identified the osteoclast progenitors in
the PPAR-expressing hematopoietic bone marrow cell pop-
ulation, and we can prospectively visualize, isolate, and char-
acterize the osteoclast progenitors using the PPAR-GFP re-
porter mice.
Osteoclast progenitors reside in quiescent PPAR bone
marrow cells. The inducible PPAR-tTA TRE-H2BGFP re-
porter mice afforded a tool for osteoclast stem/progenitor
cell marking by H2BGFP label retention, a quality that is
often indicative of quiescent stem/progenitor cell popula-
FIG. 2. Osteoclast progenitors reside in quiescent PPAR bone marrow cells. (A) Schematic diagram of the in vivo marking of osteoclast
stem/progenitor cells. (B) A pulse-chase strategy labels the quiescent PPAR stem/progenitor cells as LRCs. (C) Lineage tracing of mature
osteoclasts from PPAR progenitors using an indelible LacZ reporter (left) and a chaseable GFP reporter (right). OcP, osteoclast progenitor/
precursors; B, bone; BM, bone marrow. Scale bars, 25 m. (D) Percentage of LRCs or GFP cells that formed osteoclasts when plated at a single
cell per well (n  96). (E to G) Flow cytometry analyses of the LRC, GFP, and GFP bone marrow populations (n  6). The error bars indicate
SD. (E) Percentages of total GFP cells and LRCs in the bone marrow. (F) Percentage of cells expressing stem/progenitor cell markers (C-Kit,
Sca-1, CD135, SiglecF, or Notch1), macrophage marker (CD11b), or erythrocyte marker (Ter119) in each population. For P values, the asterisks
compare total GFP cells or LRCs with GFP cells and the pluses compare LRCs with total GFP cells. (G) Percentage of cells expressing CD45,
CD115 (M-CSFR; c-fms), or CD265 (RANK). *, P 
 0.05; , P 
 0.01; ***, P 
 0.005; ****, P 
 0.001; ***** or , P 
 0.0005;
****** or , P 
 0.0001.
VOL. 31, 2011 PPAR MARKS OSTEOCLAST PROGENITORS 4695
 o
n
 Septem
ber 12, 2018 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
4696 WEI ET AL. MOL. CELL. BIOL.
 o
n
 Septem
ber 12, 2018 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
tions (51). Histone H2B-GFP has been well characterized as
a stable protein and a sensitive marker for chromosome
dynamics in living cells (26, 51). In the absence of doxycy-
cline (Dox), all PPAR cells are labeled with GFP. When
tTA activity is suppressed by Dox, only postmitotic and
quiescent stem/progenitor cells retain the label, as H2BGFP
is diluted in proliferating cells (26; http://www4
.utsouthwestern.edu/wanlab/publications.htm) (Fig. 2A).
Thus, we employed a pulse-chase strategy to distinguish
slow-cycling (quiescent progenitor) from fast-cycling (pro-
liferating precursor) cells (Fig. 2B). We first pulsed the
reporter mice by allowing GFP expression in all PPAR
cells (Dox) and then chased with Dox for 8 weeks to block
new H2BGFP expression and thus mark only the label-
retaining cells (LRCs). Terminally differentiated osteoclasts
are also GFP and no longer proliferate. However, oste-
oclasts undergo constant turnover, with a half-life of 1.3
days in mice (32). Thus, the initial GFP osteoclasts were
eliminated by apoptosis and replaced by osteoclasts differ-
entiated from GFP precursors by the end of the 8-week
Dox chase (Fig. 2B). Previous studies have shown that 4
weeks to 4 months of Dox chase is sufficient to label pro-
genitors as LRCs (26). In our study, we consistently Dox
chased the mice for 8 weeks to ensure both proliferating
precursors and mature osteoclasts became GFP. There-
fore, this pulse-chase strategy labels osteoclast progenitors
as LRCs in the bone marrow.
To determine whether mature osteoclasts can be lineage
traced to PPAR progenitors, we employed both a prolifer-
ation-sensitive chaseable marker (H2BGFP) and a prolifera-
tion-insensitive indelible marker (LacZ) for PPAR cells
(http://www4.utsouthwestern.edu/wanlab/publications.htm). In
the PPAR-tTA TRE-H2BGFP reporter, only quiescent
PPAR progenitors remain GFP after Dox suppression of
tTA activity, whereas in the PPAR-tTA TRE-Cre ROSA-
LacZ reporter, all cells that originate from PPAR progen-
itors before Dox suppression at postnatal day 2 (P2) remain
LacZ, since the cre-flox recombination event is irreversible
(http://www4.utsouthwestern.edu/wanlab/publications.htm). Thus,
the combination of these two markers allows lineage tracing of
PPAR progenitors. The results showed that mature oste-
oclasts indeed originated from PPAR progenitors, because
they became GFP but still remained LacZ after the Dox
chase (Fig. 2C). To quantify the purity of osteoclast progeni-
tors in the hematopoietic LRC population, we FACS sorted
LRCs and plated them at a single cell per well in 96-well plates
to assess their ability to differentiate into osteoclasts. The re-
sults showed that 94% of LRCs (Dox) formed osteoclasts
(90/96) whereas only 1% of GFP cells (Dox) formed oste-
oclasts (1/96) (Fig. 2D), indicating that the LRCs specifically
labeled osteoclast progenitors.
We next further characterized the LRC (Dox), GFP
(Dox), and GFP (Dox) populations by FACS analysis.
First, LRCs represented 1/3 of the total GFP cells (Fig.
2E). Second, stem/progenitor cell markers, including c-Kit
(2, 24, 60), Sca-1 (44), CD135 (33), Siglec-F (3), and
Notch-1 (6), were further enriched in the LRCs compared
with either total GFP or GFP (Fig. 2F) cells, whereas the
macrophage marker CD11b was reduced in LRCs (Fig. 2F),
indicating an increase in non-lineage-committed progenitors
(4). Third, the erythrocyte marker Ter119 was excluded
from both total GFP cells and LRCs (Fig. 2F). Fourth,
	95% of LRCs expressed the leukocyte common antigen
CD45, a marker found on all cells of hematopoietic origin
except mature erythrocytes and platelets (23) but not on
cells of mesenchymal origin (9), demonstrating that the
LRCs purified by our method did not contain significant
mesenchymal cell types (Fig. 2G). Fifth, 93% of total GFP
cells and 85% of LRCs expressed CD115 (M-CSFR; c-fms),
and 68% of total GFP cells and 12% of LRCs expressed
CD265 (RANK), a receptor required for osteoclast precur-
sors but not for myeloid progenitors or macrophages (15)
(Fig. 2G). These results not only confirmed the microarray
analysis (Fig. 1I) showing that the GFP population was
highly enriched for the stem/progenitor cells of the mono-
cyte/macrophage lineage, but also identified the LRC sub-
population as the osteoclast progenitors.
Constitutive activation of Notch signaling in PPAR cells
causes high bone mass. Notch signaling is a key regulator of
osteoblastogenesis (17); however, the cell-autonomous func-
tion of Notch in osteoclastogenesis is incompletely understood.
We found that Notch1 expression was 15-fold higher in LRCs
than in total GFP cells (Fig. 2F), indicating that Notch sig-
naling may regulate the quiescence-to-proliferation switch of
the osteoclast progenitors. A previous study showed that loss
of Notch function by Notch1 to -3 deletion enhances osteoclas-
togenesis by promoting osteoclast precursor proliferation (6).
Nonetheless, the effect of gain of Notch function in the oste-
oclast lineage is unknown. Thus, if PPAR cells are bona fide
osteoclast progenitors, then Notch activation in these cells
should impair osteoclastogenesis by restraining the quies-
cence-to-proliferation switch. To test this hypothesis, we ex-
FIG. 3. Notch activation in PPAR-expressing cells causes high bone mass. (A) Schematic diagram of PTNICD mice. (B and C) CT analysis
of the tibiae from PTNICD or control mice (5 months old; male; n  6). (B) Representative images of the trabecular bone of the tibial metaphysis
(top; scale bar, 10 m) and the entire proximal tibia (bottom; scale bar, 1 mm). Ctrl, control. (C) Quantification of trabecular bone volume and
architecture. BS, bone surface; Tb.N, trabecular number; Tb.Sp, trabecular separation. The error bars indicate SD. (D) Urinary CTX-1 (normal-
ized to urinary creatinine) (n  6). (E) Serum osteocalcin (n  6). (F and G) Bone histomorphometry (n  6). (F) Representative images of
TRAP-stained femoral sections. Scale bar, 100 m. (G) Quantification of osteoclast surface (Oc.S/B.S) and number (Oc.N/B.Ar); B.Ar, bone area.
(H) PTNICD mice exhibited extramedullary hematopoiesis in the spleen (n  6). (I) Osteoclast precursor proliferation was decreased in the
PTNICD cultures. (Left) Schematic diagram of the proliferation assay. (Right) Quantification of BrdU incorporation (n 3). (J and K) Osteoclast
differentiation was blunted in the PTNICD culture. (J) Representative images of TRAP-stained osteoclast differentiation cultures. Scale bar, 25
m. (K) Representative osteoclast marker expression (n  3). R, RANKL; V, vehicle; B, BRL. (L) NICD expression in control or PTNICD
differentiation culture (n  3). (M) Tibial RANKL/OPG mRNA ratio in control or PTNICD mice (n  3). *, P 
 0.05; **, P 
 0.01; ***, P 

0.005; ****, P 
 0.001; *****, P 
 0.0005; n.s., nonsignificant (P 	 0.05).
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ploited the PPAR-tTA system, which enables not only oste-
oclast progenitor marking but also genetic manipulation
therein. Specifically, PPAR-tTA TRE-Cre mice permit rapid
translation to in vivo models harboring flox-mediated inducible
gene deletion or activation in osteoclast progenitors. To ex-
press a constitutively active Notch intracellular domain
(NICD) in the osteoclast lineage, we bred PPAR-tTA TRE-
Cre mice with Stopflox/flox-NICD mice (55) to generate
PTNICD mice (Fig. 3A).
Skeletal examinations indicated that the PTNICD mice de-
veloped high bone mass due to osteoclast defects. First, CT
imaging revealed a significant increase in trabecular bone in
the PTNICD mice (Fig. 3B and C). Second, ELISA analyses
showed that the bone resorption marker CTX-1 was markedly
decreased by 56% (Fig. 3D) while the bone formation marker
osteocalcin was unaltered (Fig. 3E). Third, histomorphometry
showed that osteoclast surface and number (Oc.S/B.S and
Oc.N/B.Ar) were significantly reduced (Fig. 3F and G), while
osteoblast surface and number (Ob.S/B.S and Ob.N/B.Ar)
were unaltered (http://www4.utsouthwestern.edu/wanlab
/publications.htm). As often observed in osteopetrotic mice,
PTNICD mice also exhibited extramedullary hematopoiesis in
the spleen (Fig. 3H). These data suggested that the increased
bone mass resulted mainly from decreased osteoclast numbers
and bone resorption.
To assess the stage at which Notch activation blocks oste-
oclastogenesis and the cell-autonomous nature of the effects,
we analyzed the osteoclast progenitors ex vivo. M-CSF-medi-
ated osteoclast precursor proliferation was markedly reduced
in the PTNICD cultures (Fig. 3I). Consistently, the bone mar-
row cells from PTNICD mice exhibited lower expression of
RANK, PPAR1, and c-fms than controls (http://www4
.utsouthwestern.edu/wanlab/publications.htm). Moreover,
RANKL-mediated and BRL-stimulated osteoclast differentia-
tion was also blunted (Fig. 3J), and induction of osteoclast
marker genes was severely decreased (Fig. 3K). NICD expres-
sion was significantly increased (Fig. 3L). In contrast, the tibial
RANKL/OPG mRNA ratio was unaltered (Fig. 3M). These
results all indicate that the impaired bone resorption in
PTNICD mice was due to an osteoclast-autonomous defect.
The simultaneous reduction in precursor proliferation and os-
teoclast differentiation suggested that Notch activation in
PPAR cells prevented the quiescence-to-proliferation
switch of the osteoclast progenitors. This was consistent with
the previous loss-of-function study showing that Notch is re-
quired to maintain the osteoclast stem cell fate (6). Impor-
tantly, these results demonstrated that osteoclast progenitors
indeed reside in the PPAR bone marrow population in vivo
and can be marked and genetically manipulated by the
PPAR-tTA system.
Ablation of PPAR cells causes high bone mass. To assess
whether selective partial ablation of PPAR cells by “diph-
theria toxin attenuated” (DTA) (30) prevents osteoclastogen-
esis in vivo, we bred PPAR-tTA TRE-Cre mice with Stopflox/flox-
DTA mice to generate PTDTA mice (Fig. 4A). We found
that the PTDTA mice also exhibited high bone mass. CT
revealed higher trabecular bone mass (Fig. 4B and C). CTX-1
was 72% lower (Fig. 4D), while osteocalcin was unaltered (Fig.
4E). Osteoclast surface and numbers were decreased (Fig. 4F
and G), while osteoblast surface and numbers were unaltered
(http://www4.utsouthwestern.edu/wanlab/publications.htm). Con-
sistently, the PTDTA mice also exhibited extramedullary hema-
topoiesis in the spleen (Fig. 4H). These data indicated that the
increased bone mass in the PTDTA mice was mainly caused by
decreased osteoclast numbers and bone resorption.
Because this bone phenotype may be contributed by other
PPAR-expressing cell types, such as adipocytes, we next in-
vestigated the cell-autonomous nature of the resorption de-
fects by examining the osteoclastogenic potential of the bone
marrow from PTDTA mice ex vivo. While many osteoclasts
developed in control cultures, few formed in PTDTA cultures
(Fig. 4I and J). This was due to cell ablation and, consequently,
decreased BrdU incorporation (Fig. 4K). Thus, ablation of
PPAR cells severely blunted osteoclastogenesis and bone
resorption. Together, the PTNICD and PTDTA genetic mod-
els provide compelling in vivo evidence that the osteoclast
lineage resides in the PPAR bone marrow population under
physiological conditions.
Ovariectomy activation of osteoclast progenitors. Estrogen
deficiency, from menopause or ovariectomy (OVX), is an im-
portant cause of osteoporosis and debilitating fractures. Cur-
rent notions indicate that estrogen deficiency enhances oste-
oclast survival (27, 34), but its specific effects on osteoclast
progenitors remain unknown. To track the response of the
osteoclast lineage to estrogen loss, we performed sham oper-
ations or ovariectomies on PPAR-GFP reporter mice in the
setting of placebo or Dox-induced reporter suppression, cou-
pled with BrdU labeling 24 h before FACS analysis (Fig. 5A).
We found that OVX significantly increased the GFP bone
marrow population by 3.8-fold (Fig. 5B). This increase ap-
peared secondary to enhanced cell proliferation, as both the
percentage of BrdU cells in the GFP population and the
percentage of BrdU/GFP cells in the entire bone marrow
population were elevated by 1.8- and 6.4-fold, respectively
(Fig. 5C and D).
Next, we examined the effects of OVX on osteoclast pro-
FIG. 4. Ablation of PPAR-expressing cells causes high bone mass. (A) Schematic diagram of the PTDTA mice. (B and C) CT analysis of
tibiae from PTDTA or control mice (7 months old; female; n  5). (B) Representative images of the trabecular bone of the tibial metaphysis (top;
scale bar, 10 m) and the entire proximal tibia (bottom; scale bar, 1 mm). (C) Quantification of trabecular bone volume and architecture. The error
bars indicate SD. (D) Urinary CTX-1 (n  5). (E) Serum osteocalcin (n  5). (F and G) Bone histomorphometry (n  5). (F) Representative
images of TRAP-stained femoral sections. Scale bar, 100 m. (G) Quantification of osteoclast surface and numbers. (H) PTDTA mice exhibited
extramedullary hematopoiesis in the spleen (n  5). (I and J) Osteoclast differentiation was blunted in the PTDTA culture. (I) Representative
images of TRAP-stained osteoclast differentiation culture. Scale bar, 25 m. (J) Numbers of mature osteoclasts per well (n  3). (K) Osteoclast
precursor proliferation was decreased in the PTDTA culture (n  3). *, P 
 0.05; **, P 
 0.01; ***, P 
 0.005; ****, P 
 0.001; *****, P 

0.0005; n.s., nonsignificant (P 	 0.05).
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genitors (LRCs; Dox) (Fig. 5E) and osteoclast precursors
(total GFP; Dox) (Fig. 5F). We observed that the percent-
age of LRCs in total GFP cells (LRC/GFP) was 15% in
OVX mice compared to 66% in sham controls (66%), resulting
in a 4.2-fold reduction (Fig. 5B). The percentage of stem cells
(Notch-1) was decreased, while the percentage of progenitor
cells (Sca1 or c-Kit) was increased (Fig. 5E and F). These
results suggested that OVX triggered the quiescence-to-prolif-
eration switch of the osteoclast progenitors. Furthermore,
Siglec-F is predominantly expressed in immature myelomono-
cytic precursors, and its expression is reduced upon macro-
phage/osteoclast differentiation (3). We found that the per-
centage of Siglec-F cells was increased in the LRCs but
decreased in the GFP population (Fig. 5E and F), suggesting
that OVX triggered not only the proliferation of the LRC
progenitors, but also the differentiation of the GFP precur-
sors. This notion was further illustrated by the elevated per-
centage of monocyte/macrophage lineage-committed cells
(CD11b) (Fig. 5E and F). Moreover, osteoclast differentia-
tion assays showed that when equal numbers of GFP cells
were seeded, more osteoclasts formed for the OVX mice than
for the sham-treated controls (Fig. 5G), indicating that OVX
increased both the number of GFP cells in the bone marrow
and their differentiation potential. Consequently, OVX led to
increased resorption (Fig. 5H). Together, these results indicate
that OVX activated both the quiescence-to-proliferation
switch in osteoclast progenitors and the proliferation-to-differ-
entiation switch in osteoclast precursors (Fig. 5I), revealing
previously unrecognized effects of estrogen deficiency on early
osteoclast lineage specification.
Pharmacological activation of osteoclast progenitors. The
tracking system also allowed us to examine the response of the
osteoclast lineage to drugs. As a model, we chose BRL, a
PPAR agonist and a diabetic drug that stimulates osteoclast
differentiation and bone resorption (52, 53, 59). In ex vivo
cultures, BRL attenuated M-CSF-mediated osteoclast precur-
sor proliferation (Fig. 6A) yet exacerbated RANKL induction
of osteoclast markers (c-fos and TRAP) (Fig. 6B), suggesting
FIG. 5. Ovariectomy triggers osteoclast progenitors to differentiate. (A) Flow chart of the pulse-chase experiment in OVX mice and sham-
treated controls (2 months old; female; n  4). (B) Percentages of total GFP and LRC populations in bone marrow cells. The error bars indicate
SD. (C) Percentage of BrdU cells in the total GFP bone marrow population. (D) Percentage of GFP/BrdU cells in the entire bone marrow
population. (E) Percentages of cells expressing stem/progenitor cell markers (Notch-1, Sca-1, C-Kit, or Siglec-F) and monocyte/macrophage
marker (CD11b) in the LRC population. (F) Percentages of cells expressing stem/progenitor cell markers (Notch-1, Sca-1, C-Kit, or Siglec-F) and
monocyte/macrophage marker (CD11b) in the total GFP population. (G) Osteoclast differentiation assay of GFP bone marrow cells from OVX
mice and sham-treated controls (n  3). (H) Urinary CTX-1. (I) Model of OVX stimulation of osteoclast precursor proliferation and differen-
tiation. (Left) The pink arrows indicate OVX-induced changes in each cell population. (Right) The pink triangle and the black trapezoid illustrate
the relative subpopulation distributions in OVX and sham-treated mice. *, P 
 0.05; **, P 
 0.01; ***, P 
 0.005; *****, P 
 0.0005; ******,
P 
 0.0001; n.s., nonsignificant (P 	 0.05).
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that PPAR activation triggers a proliferation-to-differentia-
tion switch toward osteoclasts. Interestingly, both BRL and
RANKL suppressed the mature macrophage marker (MCP-1)
(Fig. 6C), indicating that BRL promotes an osteoclast fate in
part by shifting the progenitors away from a terminal macro-
phage fate.
To determine the effects of PPAR activation on the oste-
oclast lineage in vivo, we next administered BRL or vehicle
control to the reporter mice. By 2 weeks, BRL increased the
GFP population within the marrow by 2.9-fold (Fig. 6D) yet
reduced the percentage of stem/progenitor cells (Notch1,
Sca-1, c-Kit, or CD135) in the GFP population (Fig. 6E).
We did not observe changes in these markers in the GFP
(PPAR) population, indicating that the BRL effects were
PPAR dependent (Fig. 6E). Consistently, BRL increased the
macrophage lineage-committed cells (CD11b) (Fig. 6F) (45).
Intriguingly, BRL significantly diminished the percentage of
mature macrophages in the GFP population, as both CD14 (a
lipopolysaccharide [LPS] receptor) (21) and MCP-1 (58) were
downregulated (Fig. 6G). In contrast, BRL increased the os-
teoclast surface (Fig. 6H) and the bone resorption marker
CTX-1 (Fig. 6I), leading to a decreased bone volume/tissue
volume (BV/TV) ratio (Fig. 6H) but unaltered bone mineral
density (BMD) (not shown). These in vivo data were consistent
with the ex vivo results (Fig. 6B and C), indicating that ligand
activation of PPAR triggered the osteoclast progenitors to
FIG. 6. Ligand activation of PPAR triggers osteoclast progenitors to differentiate. (A) BRL attenuated osteoclast precursor proliferation ex
vivo (n  3). The error bars indicate SD. (B and C) BRL stimulated RANKL-mediated induction of osteoclast markers (B) but inhibited mature
macrophage markers (C) during a 6-day time course of ex vivo osteoclast differentiation (n  3). The arrows indicate the addition of M-CSF at
day 0 and the addition of M-CSF plus RANKL at day 3. (D to G) FACS analyses of the effects of BRL on osteoclast progenitors/precursors in
vivo. PPAR-GFP mice (6 months old; male; n  4) were treated with BRL (10 mg/kg of body weight/day) or vehicle (Veh) for 1 or 2 weeks.
(D) Percentages of GFP cells in bone marrow. (E) Percentages of cells expressing stem cell markers in GFP and GFP populations.
(F) Percentages of cells expressing pan-monocyte/macrophage marker. (G) Percentages of cells expressing mature macrophage markers. (H and
I) Effects of BRL on osteoclast number and bone resorption in vivo. Mice were treated with BRL (10 mg/kg/day) or vehicle for 8 weeks (n  4).
(H) Osteoclast surface and BV/TV ratio. (I) Urinary CTX-1. (J) Model for BRL stimulation of osteoclast differentiation in vivo. (Left) The orange
arrows indicate BRL-induced changes in each cell population. (Right) The orange triangle and the black trapezoid illustrate the relative
subpopulation distributions in BRL- and Veh-treated mice. *, P 
 0.05; **, P 
 0.01; ***, P 
 0.005; ****, P 
 0.001; ******, P 
 0.0001.
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undergo differentiation, but toward osteoclasts and away from
mature macrophages (Fig. 6J). Thus, PPAR cells are oste-
oclast progenitors, yet PPAR is also a molecular switch that
translates an increased local concentration of PPAR agonists
into enhanced osteoclast differentiation. Importantly, both
OVX and BRL, representing pathological and pharmacologi-
cal resorption-enhancing stimuli, triggered the PPAR cells
to proliferate and differentiate, further supporting the notion
that osteoclast progenitors reside in the PPAR bone mar-
row population in vivo.
PPAR promotes osteoclast progenitors by activating
GATA2 transcription. The GATA family of zinc finger tran-
scription factors is an important regulator of hematopoiesis.
GATA2 is required to generate osteoclast progenitors (50, 54),
while GATA1 is dispensable for osteoclastogenesis but essen-
tial for erythropoiesis and megakaryocyte maturation (20, 37,
43). Therefore, the GATA2/GATA1 ratio in hematopoietic
progenitors controls lineage divergence between osteoclasts
and erythrocytes/megakaryocytes. In our microarray analysis,
we found that this key GATA2/GATA1 ratio was 12.9-fold
higher in the PPAR (GFP) cells than in the PPAR
(GFP) cells (Fig. 7A), owing to elevated GATA2 expression
and diminished GATA1 expression (Fig. 7B). Since PPAR is
also critical for osteoclastogenesis (52), it may promote oste-
oclast progenitor commitment by activating GATA2 transcrip-
tion.
To test this hypothesis, we examined the GATA2 promoter
and identified three highly conserved PPAR response elements
(PPREs) (Fig. 7C). To determine whether PPAR directly
binds to the mouse GATA2 promoter and induces its tran-
scription, we performed a ChIP assay with antibodies for
PPAR or acetylated histone H3, a chromatin marker for
activated transcription. In GFP cells, but not GFP control
cells, PPAR bound to all three PPREs in the mGATA2 pro-
moter, accompanied by elevated levels of acetylated histone
H3 (Fig. 7D); in contrast, PPAR did not bind to the GATA1
promoter (not shown), suggesting that PPAR inhibits
GATA1 expression via an indirect mechanism. PU.1 binding
was also detected in these GATA2 regions, suggesting that
PPAR colocalization with PU.1 in the GFP cells specified
GATA2 expression and osteoclast progenitors (Fig. 7D). We
next assessed the functional requirement for GATA2 by both
gain- and loss-of-function analyses. Ectopic GATA2 expres-
sion in PPAR cells to a level comparable to that in PPAR
cells partially rescued the osteoclast differentiation blockade
(Fig. 7E). Conversely, GATA2 knockdown severely diminished
both RANKL-mediated and BRL-stimulated osteoclast differ-
entiation in the PPAR cells (Fig. 7F). Together, these re-
sults indicate that PPAR promotes osteoclast progenitor
commitment, at least in part, by directly binding to the GATA2
promoter and activating its transcription (Fig. 7G).
DISCUSSION
The cellular identity and precise nature of osteoclast pro-
genitors are longstanding and important biological questions.
Based on our cellular, molecular, genetic, pathological, and
pharmacological evidence, in vivo and ex vivo, we conclude that
the osteoclast lineage resides in the PPAR-expressing hema-
topoietic bone marrow cell population, and we have identified
the quiescent PPAR bone marrow cells as the osteoclast
progenitors. Importantly, we have established PPAR-tTA
TRE-H2BGFP reporter mice as an unprecedented tool to
visualize, isolate, quantify, and trace the lineage of osteoclast
progenitors. As a complement, we have also established
PPAR-tTA TRE-Cre mice as a genetic tool to interrogate the
function and regulation of osteoclast progenitors in vivo by
inducing flox-mediated gene deletion or activation. Using
these tools, we have uncovered previously unrecognized effects
of ovariectomy and rosiglitazone, two resorption-enhancing
stimuli, on the early osteoclast lineage. Mechanistically, we
have identified GATA2 as a novel yet critical PPAR target
gene in osteoclast progenitors. Therefore, both conceptually
and technically, this study opens an exciting new path to the
fundamental understanding of both osteoclast lineage specifi-
cation and PPAR function.
In the PPAR-tTA TRE-H2BGFP reporter mice, GFP
cells also label adipocyte progenitors and mature adipocytes
(46). Intriguingly, several reports show that mammalian cells of
the adipocyte lineage and the macrophage lineage share nu-
merous functional and antigenic properties. Gene expression
profiling revealed that preadipocytes share a surprisingly closer
signature with macrophages than with adipocytes, and preadi-
pocytes can be effectively converted to macrophages in a mac-
rophage environment (10). This appears to be an evolution-
arily conserved phenomenon, because in invertebrates, such as
Drosophila, hemocytes (blood cells) and fat bodies also share
the expression of fate-determining genes (14). Our findings
that PPAR cells label both adipocyte progenitors and mac-
rophage/osteoclast progenitors provided mechanistic evidence
for convergence and/or plasticity in the adipocyte and macro-
phage lineage specification. Together with the dual roles of
PPAR ligand in stimulating both adipogenesis and osteoclas-
togenesis, our findings illuminate a potential molecular basis
for the close correlation between insulin-sensitizing effects and
bone loss effects, as well as the emerging connections between
fat and bone.
Stem/progenitor cells are defined as multipotent; hence, in
order to target osteoclast progenitors experimentally, it is im-
possible to completely rule out other differentiation outcomes,
and specificity is only relative. For example, Tie2 labels not
only osteoclast progenitors, but also all other hematopoietic
progenitors, as well as endothelial cells (13, 52), whereas
PPAR labels osteoclast and adipocyte progenitors but not
other hematopoietic lineages (Fig. 1 and 2). The advantages of
the PPAR-tTA-based mouse models include the following: (i)
they distinguish macrophages/osteoclasts from other hemato-
poietic lineages; (ii) they target the entire osteoclast lineage,
including osteoclast progenitors and mature osteoclasts; and
(iii) they permit temporal control of inducible cell labeling and
genetic manipulations in the osteoclast lineage. Our results
show that osteoclast progenitors are 140-fold enriched in the
PPAR bone marrow cell population, and thus, only 
1% of
osteoclast progenitors may be derived from PPARlow or
PPAR cells. Moreover, previous studies have documented
that Notch activation in lymphoid progenitors causes T-cell
lymphoblastic leukemia in humans and mice (16, 36). In our
study, PTNICD mice did not develop lymphoma, which further
supports the notion that PPAR specifically directs hemato-
poiesis toward the monocyte/macrophage lineage and that the
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FIG. 7. PPAR promotes osteoclast progenitors by activating GATA2 transcription. (A) GATA2/GATA1 mRNA ratio in GFP and
GFP bone marrow populations (n  2). The error bars indicate SD. (B) GATA2 and GATA1 mRNA expression (n  2). (C) Alignment
of mouse (m), rat (r), and human (h) GATA2 promoter PPRE regions, together with known PPREs for ap2, PEPCK, ACS, and DR-1
consensus. (D) ChIP analysis of PPAR or PU.1 binding and histone H3 acetylation in the mGATA2 promoter PPRE regions in GFP and
GFP bone marrow cells. For P values, the asterisks (or n.s.) compare each antibody with IgG control in the same cell population; the pluses
compare the same antibody in GFP cells with GFP cells (n  3). (E) Osteoclast differentiation blockade in PPAR cells was partially
rescued by ectopic GATA2 expression. Hematopoietic bone marrow cells were transfected with GATA2-expressing plasmid or vector
control. Osteoclast differentiation was quantified by TRAP expression (left), and GATA2 protein was quantified by Western blotting (IB)
(right). The P values compare GATA2-transfected GFP cells with vector-transfected GFP cells; GFP cells served as a positive control.
(F) RANKL-induced and BRL-stimulated osteoclast differentiation in PPAR cells was severely diminished by GATA2 knockdown.
Hematopoietic bone marrow cells were transfected with GATA2 siRNA (siGATA2) or control siRNA (siCtrl). Osteoclast differentiation was
quantified by TRAP expression (left), and GATA2 protein was quantified by Western blotting (right). The P values compare siGATA2-
transfected GFP cells with siCtrl-transfected GFP cells; GFP cells served as a negative control. (G) Model for PPAR regulation of
osteoclastogenesis. PPAR expression promotes osteoclast progenitor specification by activating GATA2 transcription. Upon PPAR
agonist availability, the ligand-activated PPAR/RXR receptor complex recruits coactivator PGC1 and induces c-fos transcription,
thereby stimulating RANKL-mediated osteoclast differentiation. HSC, hematopoietic stem cells. * or , P 
 0.05; ** or , P 
 0.01; ***
or , P 
 0.005; ****, P 
 0.001; ***** or , P 
 0.0005; ****** or , P 
 0.0001; n.s., nonsignificant (P 	 0.05).
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PPAR-expressing bone marrow population does not contain
lymphoid progenitors. Since PPAR also labels adipocyte pro-
genitors (46), it is possible that Notch constitutive activation in
PTNICD mice may also affect other PPAR cells, such as
adipocytes, in addition to osteoclast progenitors.
Several drivers targeting macrophage precursors or mature
osteoclasts have been elegantly described; nonetheless, be-
cause they do not target osteoclast progenitors, they are not
suitable for in vivo study of early osteoclast lineage specifica-
tion. For example, CD11b or lysozyme drivers are useful to
target macrophage precursors because they are upregulated
only upon macrophage differentiation (12, 19, 25). In addition,
Ctsk or TRAP drivers are useful to target preosteoclasts and
mature osteoclasts because they are upregulated only upon
osteoclast differentiation (11, 34). Therefore, the PPAR-tTA-
based models represent a novel osteoclast progenitor-targeting
strategy that is complementary to other existing models for the
comprehensive investigation of osteoclast lineage specification
and differentiation.
Indeed, the PTNICD and PTDTA genetic models provide
compelling in vivo evidence that the osteoclast lineage resides
in the PPAR bone marrow population under physiological
conditions; in particular, the PTNICD model supports the no-
tion that PPAR cells represent osteoclast progenitors. In the
PTDTA model, the DTA was an “attenuated” version of diph-
theria toxin, thus explaining the relatively mild bone pheno-
type, which was supported by the survival of the PTDTA mice
in contrast to the embryonic lethality in the global PPAR
knockout (KO) mice (7, 28, 40). Furthermore, both OVX and
BRL, representing pathological and pharmacological resorp-
tion-enhancing stimuli, triggered the PPAR cells to prolif-
erate and differentiate, further supporting the notion that os-
teoclast progenitors reside in the PPAR bone marrow
population in vivo. The rapid increase (1 to 2 weeks) in the
percentage of GFP bone marrow cells in response to BRL
treatment in vivo indicates that this effect was not likely sec-
ondary to any BRL alteration of adipocytes followed by
changes in hematopoiesis, which takes at least 4 weeks (1).
The Ets family transcription factor PU.1 is essential for the
development of both myeloid and B-lymphoid cells (42). This
suggests that additional transcription factors are required to
function in combination with PU.1 and confer lineage speci-
ficity (22). Since osteoclasts are of myeloid lineage, PU.1 is also
essential for the generation of osteoclast progenitors. Indeed,
PU.1 deletion in mice precludes osteoclast development, lead-
ing to arrested bone resorption and osteopetrosis (47). A re-
cent study revealed that, in macrophages, PPAR colocalizes
with PU.1 in areas of open chromatin and histone acetylation
near a distinct set of hematopoietic genes (31). Our results
suggest that in the PPAR cells, PPAR cooperates with
PU.1 to activate the transcription of a subset of genes, includ-
ing GATA2, thereby directing macrophage/osteoclast lineage
commitment. In contrast, in the PPAR cells, the absence of
PPAR prevents GATA2 transcription and alters the subset of
genes regulated by PU.1, thereby directing B-lymphoid lineage
commitment. Therefore, our identification of PPAR bone
marrow cells as osteoclast progenitors provides in vivo evi-
dence for the notion that the collaborative interaction between
PPAR and PU.1 on a subset of promoters is essential to
activate the transcriptional program required for macrophage/
osteoclast lineage commitment. Furthermore, our results sug-
gest that the expression of PPAR, rather than the ligand
activation of PPAR, promotes osteoclast progenitor specifi-
cation by enhancing GATA2 expression, which is downregu-
lated during the quiescence-to-proliferation switch and thus
is absent in osteoclast precursors (53a) (Fig. 7G). Together,
our current and previous studies reveal that PPAR plays
dual roles in osteoclastogenesis that involve multiple mech-
anisms and target genes (Fig. 7G): PPAR expression pro-
motes osteoclast progenitors by inducing GATA2, and
PPAR ligand activation stimulates osteoclast differentia-
tion by inducing c-fos.
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